Observed best responses by AML subset
| . | All treated (N = 53), % . | Secondary AML (n = 24), % . | ≥75 y old (n = 29), % . | FLT3/ITD+ (n = 5), % . | MRC adv (n = 20), % . | Und. Myelo (n = 23), % . |
|---|---|---|---|---|---|---|
| CR | 43 | 42 | 34 | 80 | 50 | 39 |
| CRi | 26 | 33 | 28 | 20 | 30 | 35 |
| mLFS | 4 | 4 | 3 | 0 | 0 | 9 |
| CRc rate | 70 | 75 | 62 | 100 | 80 | 74 |
| Blast clearance | 74 | 79 | 66 | 100 | 80 | 83 |
| . | All treated (N = 53), % . | Secondary AML (n = 24), % . | ≥75 y old (n = 29), % . | FLT3/ITD+ (n = 5), % . | MRC adv (n = 20), % . | Und. Myelo (n = 23), % . |
|---|---|---|---|---|---|---|
| CR | 43 | 42 | 34 | 80 | 50 | 39 |
| CRi | 26 | 33 | 28 | 20 | 30 | 35 |
| mLFS | 4 | 4 | 3 | 0 | 0 | 9 |
| CRc rate | 70 | 75 | 62 | 100 | 80 | 74 |
| Blast clearance | 74 | 79 | 66 | 100 | 80 | 83 |
adv, adverse; Int, intermediate; ITD, internal tandem duplication; mLFS, morphologic leukemia-free state; myelo, myelodysplasia; Und, underlying.